Inhibition of nuclear factor-kappa B by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells


Autoria(s): Castro-Gamero, Angel Mauricio; Borges, Kleiton Silva; Silveira, Vanessa da Silva; Peixoto Lira, Regia Caroline; Gomes Queiroz, Rosane de Paula; Pereira Valera, Fabiana Cardoso; Scrideli, Carlos Alberto; Umezawa, Kazuo; Tone, Luiz Gonzaga
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

22/10/2013

22/10/2013

2012

Resumo

Osteosarcoma (OS) is the most common primary malignant bone tumor, usually developing in children and adolescents, and is highly invasive and metastatic, potentially developing chemoresistance. Thus, novel effective treatment regimens are urgently needed. This study was the first to investigate the anticancer effects of dehydroxymethylepoxyquinomicin (DHMEQ), a highly specific nuclear factor-kappa B (NF-kappa B) inhibitor, on the OS cell lines HOS and MG-63. We demonstrate that NF-kappa B blockade by DHMEQ inhibits proliferation, decreases the mitotic index, and triggers apoptosis of OS cells. We examined the effects of combination treatment with DHMEQ and cisplatin, doxorubicin, or methotrexate, drugs commonly used in OS treatment. Using the median effect method of Chou and Talalay, we evaluated the combination indices for simultaneous and sequential treatment schedules. In all cases, combination with a chemotherapeutic drug produced a synergistic effect, even at low single-agent cytotoxic levels. When cells were treated with DHMEQ and cisplatin, a more synergistic effect was obtained using simultaneous treatment. For the doxorubicin and methotrexate combination, a more synergistic effect was achieved with sequential treatment using DHMEQ before chemotherapy. These synergistic effects were accompanied by enhancement of chemoinduced apoptosis. Interestingly, the highest apoptotic effect was reached with sequential exposure in both cell lines, independent of the chemotherapeutic agent used. Likewise, DHMEQ decreased cell invasion and migration, crucial steps for tumor progression. Our data suggest that combining DHMEQ with chemotherapeutic drugs might be useful for planning new therapeutic strategies for OS treatment, mainly in resistant and metastatic cases. Anti-Cancer Drugs 23:638-650 (C) 2012 Wolters Kluwer Health broken vertical bar Lippincott Williams & Wilkins.

CAPES

CAPES

FAEPA

FAEPA

Identificador

ANTI-CANCER DRUGS, PHILADELPHIA, v. 23, n. 6, supl. 1, Part 1, pp. 638-650, JUL, 2012

0959-4973

http://www.producao.usp.br/handle/BDPI/35414

10.1097/CAD.0b013e328350e835

http://dx.doi.org/10.1097/CAD.0b013e328350e835

Idioma(s)

eng

Publicador

LIPPINCOTT WILLIAMS & WILKINS

PHILADELPHIA

Relação

ANTI-CANCER DRUGS

Direitos

closedAccess

Copyright LIPPINCOTT WILLIAMS & WILKINS

Palavras-Chave #APOPTOSIS #CHEMOSENSITIZATION #DEHYDROXYMETHYLEPOXYQUINOMICIN #DRUG COMBINATION #NUCLEAR FACTOR-KAPPA B INHIBITOR #OSTEOSARCOMA #PROSTATE-CANCER CELLS #TUMOR-NECROSIS-FACTOR #IN-VITRO #PROGNOSTIC FACTORS #CROSS-RESISTANCE #ACTIVATION #DHMEQ #LINES #LEUKEMIA #SENSITIZATION #ONCOLOGY #PHARMACOLOGY & PHARMACY
Tipo

article

original article

publishedVersion